Chromogranin A as a diagnostic marker of pheochromocytoma and paraganglioma: A systematic review and meta‐analysis
International Journal of Urology · 2024-06 · 31 (6) · 637-645
DOI: 10.1111/iju.15423 ↗Kurz gefasst
Metaanalyse in der Zeitschrift International Journal of Urology, online erschienen am 21.02.2024. Verfasst von Yanbo Xing und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China. Hauptthemen laut MEDLINE: Pheochromocytoma, Chromogranin A, Adrenal Gland Neoplasms, Paraganglioma. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Objectives
This work aims to assess the diagnostic value of chromogranin A (CgA) in the laboratory diagnosis of neuroendocrine tumors classified as pheochromocytoma and paraganglioma (PPGL).
Methods
A comprehensive search was performed in PubMed, Embase, the Cochrane Library, and Web of Science databases to obtain relevant studies reporting the diagnostic accuracy of CgA in patients with PPGL. The search involved studies written in English between the time of library inception and May 1, 2023. We computed the pooled sensitivity, specificity, and diagnostic odds ratio (DOR). Additionally, the receiver operating characteristic curve and area under the curve (AUC) were determined. The heterogeneity was assessed using the Chi‐square test and the I 2 test. The subgroup analyses were performed to investigate the origins of heterogeneity. Stata 15.1 statistical software was used in all data analyses.
Results
This meta‐analysis included 13 studies involving 1470 patients. CgA had a pooled diagnostic sensitivity of 0.86 (95% CI 0.81–0.91), a specificity of 0.90 (95% CI 0.81–0.95), and a DOR of 57 (95% CI 23–142). CgA had an AUC of 0.93. The studies did not reveal any threshold effect ( r = −0.165; p > 0.05). The subgroup analyses revealed that the control group category and the detection method caused the overall heterogeneity.
Conclusions
Our study suggests that CgA is a helpful PPGL biomarker. However, relying solely on CgA for diagnosis is not advisable. A comprehensive approach is essential for accurate diagnosis. Future large‐scale research is needed to refine CgA's clinical application.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.
- Second Clinical Medical College, Shanxi Medical University, Taiyuan, Shanxi, China.
ORCID-Profile: Yanbo Xing, Chuan Hao
Zitieren
APA
Xing, Y., Shi, H., Guo, Q., Wang, C., Li, C., & Hao, C. (2024). Chromogranin A as a diagnostic marker of pheochromocytoma and paraganglioma: A systematic review and meta‐analysis. International Journal of Urology, 31(6), 637-645. https://doi.org/10.1111/iju.15423
Vancouver
Xing Y, Shi H, Guo Q, Wang C, Li C, Hao C. Chromogranin A as a diagnostic marker of pheochromocytoma and paraganglioma: A systematic review and meta‐analysis. International Journal of Urology. 2024;31(6):637-645. doi:10.1111/iju.15423
BibTeX
@article{Xing2024,
author = {Xing, Yanbo and Shi, Haoying and Guo, Qiang and Wang, Cong and Li, Chengyong and Hao, Chuan},
title = {Chromogranin A as a diagnostic marker of pheochromocytoma and paraganglioma: A systematic review and meta‐analysis},
journal = {International Journal of Urology},
year = {2024},
volume = {31},
number = {6},
pages = {637--645},
doi = {10.1111/iju.15423}
}
EUVIMED